Alexion Pharmaceuticals (ALXN) CFO Successor Is A Strong Replacement - RBC
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN) after the company announced the planned ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
